Shots:
- Otsuka Pharmaceutical has reported P-III (VISIONARY) trial data evaluating Voyxact (sibeprenlimab-szsi; 400mg, SC, Q4W) vs PBO in IgAN pts at risk for disease progression
- Trial showed 82.5% vs 52.6% pts achieved negative microscopic hematuria (0–5/HPF; exploratory EP) at 48wks., with a median time to achieve 0–5/HPF was 9 vs 24wks.; data were presented at ISN WCN’26
- The trial is further evaluating the safety & efficacy of Voyxact in preserving kidney function based on eGFR slope over a 24mos. treatment period
Ref: Businesswire | Image: Otsuka | Press Release
Related News: Otsuka Pharmaceutical Reports OLE Study Data on Repinatrabit in Phenylketonuria
PharmaShots, your go-to media platform for customized news ranging across multiple indications. For more information, connect with us at connect@pharmashots.com
